Celularity Inc
CELU2.220USD
+0.030+1.37%
終値 09/19, 16:00（ET）15分遅れの株価
54.63M時価総額
損失額直近12ヶ月PER
詳細情報 Celularity Inc 企業名
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
企業情報
企業コードCELU
会社名Celularity Inc
上場日May 23, 2019
最高経営責任者「CEO」Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
従業員数123
証券種類Ordinary Share
決算期末May 23
本社所在地170 Park Ave
都市FLORHAM PARK
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号07932
電話番号19087682170
ウェブサイトhttps://celularity.com/
企業コードCELU
上場日May 23, 2019
最高経営責任者「CEO」Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.85M
+0.12%
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Vincent Levien
Mr. Vincent Levien
Director
Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.85M
+0.12%
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Wed, Sep 3
更新時刻: Wed, Sep 3
株主統計
種類
株主統計
株主統計
比率
Genting Bhd
23.74%
Hariri (Robert J)
10.70%
Starr International Company, Inc.
5.73%
Lincoln Alternative Strategies LLC
4.61%
Lung Biotechnology Inc
2.99%
他の
52.25%
株主統計
株主統計
比率
Genting Bhd
23.74%
Hariri (Robert J)
10.70%
Starr International Company, Inc.
5.73%
Lincoln Alternative Strategies LLC
4.61%
Lung Biotechnology Inc
2.99%
他の
52.25%
種類
株主統計
比率
Corporation
31.33%
Individual Investor
11.65%
Investment Advisor
8.46%
Insurance Company
2.86%
Investment Advisor/Hedge Fund
1.02%
Hedge Fund
0.34%
Research Firm
0.33%
Venture Capital
0.08%
Family Office
0.04%
他の
43.88%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
104
15.80M
65.98%
-1.41M
2025Q1
140
16.18M
70.80%
+52.81K
2024Q4
156
14.05M
63.43%
-1.62M
2024Q3
169
14.41M
66.16%
-2.07M
2024Q2
181
15.12M
69.86%
-663.91K
2024Q1
187
14.36M
66.56%
-1.48M
2023Q4
186
12.31M
65.02%
-347.56K
2023Q3
186
12.52M
68.51%
+23.28K
2023Q2
200
12.33M
70.15%
-1.64M
2023Q1
224
13.36M
90.76%
-717.66K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Genting Bhd
6.34M
26.45%
--
--
May 15, 2025
Hariri (Robert J)
2.85M
11.92%
+3.28K
+0.12%
May 15, 2025
Starr International Company, Inc.
1.53M
6.38%
--
--
May 15, 2025
Lung Biotechnology Inc
796.88K
3.33%
--
--
Dec 31, 2023
C.V. Starr & Co., Inc.
764.07K
3.19%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
500.13K
2.09%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
136.04K
0.57%
+4.53K
+3.45%
Mar 31, 2025
Diamandis (Peter)
134.31K
0.56%
-63.82K
-32.21%
May 15, 2025
BlackRock Institutional Trust Company, N.A.
99.02K
0.41%
-471.00
-0.47%
Mar 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
日付
種類
比率
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
